论文部分内容阅读
目前,以非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)为适应证的临床治疗药物研发活跃,但尚无正式批准上市的药物.现普遍认为血清丙氨酸氨基转移酶(alanine aminotransferase,ALT)升高,伴或不伴有高胆固醇血症、高甘油三酯血症,甚至血糖水平升高的非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)患者均应给予干预.生活方式改变和功能医学干预是目前的主要手段.现对1例NASH患者应用功能性医学产品“利沃素(Liversol)”治疗的临床疗效进行报道.通过对本病例的报道和相关文献的复习,以期对NASH及其干预和治疗新措施有更深入的认识.“,”Currently, the research and development of clinical therapeutic drugs with the indication of non-alcoholic fatty liver disease (NAFLD) is active, but there is no officially approved drug on the market. It is generally believed that the NASH patients with increased serum alanine aminotransferase (ALT),hypercholesterolemia, hypertriglyceridemia and even elevated blood glucose level should be intervened. Life style modification and functional medicine are the main intervened methods. This paper reported the clinical effects of a case with NASH treated with the functional medicine product “Liversol”. Through this report and the review of relevant literature, we hope to have a deeper understanding of NAFLD and its treatment.